To include your compound in the COVID-19 Resource Center, submit it here.

Amgen misses consensus

AMGN reported fourth quarter and full year EPS of $0.24 and $1.05, missing consensus estimates of $0.25 and $1.07, respectively. AMGN said that 4Q and FY EPS excluded a $0.01

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE